Insider trade

Arcutis Biotherapeutics (ARQT): Director bought ~$86K

Patrick J Heron, Director at Arcutis Biotherapeutics, bought ~$86K of Arcutis Biotherapeutics shares.

~$86K
Approx. value · 6,300 sh @ $13.60
6,300
Holds after · shares reported
Traded
May 9, 2025
Filed
May 13, 2025

What stands out in this filing

  • After this purchase the filing reports 6,300 shares, held indirectly.
  • 6,300 shares at an average of $13.60 each, as reported on the form.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 13, 2025Insider · 1 personInsiders: 2 sales (~$736K)
  2. Mar 14, 2025InsiderOfficer sold ~$184K of ARQT shares in the open market
  3. Mar 17, 2025InsiderDirector sold ~$21K of ARQT shares in the open market
  4. Mar 24, 2025InsiderDirector sold ~$26K of ARQT shares in the open market
  5. Mar 25, 2025InsiderDirector sold ~$38K of ARQT shares in the open market
  6. Apr 1, 2025InsiderDirector sold ~$151K of ARQT shares in the open market
  7. Apr 2, 2025InsiderCFO sold ~$152K of ARQT shares in the open market
  8. May 1, 2025InsiderDirector sold ~$146K of ARQT shares in the open market
  9. May 2, 2025Insider · 3 peopleInsiders: 3 sales (~$290K)
  10. May 8, 2025InsiderOfficer sold ~$53K of ARQT shares in the open market
  11. May 9, 2025 · this disclosureInsiderDirector purchased ~$86K of ARQT shares in the open market

What came next

  1. May 13, 2025InsiderDirector purchased ~$33K of ARQT shares in the open market
  2. May 14, 2025InsiderDirector purchased ~$87K of ARQT shares in the open market
  3. May 15, 2025InsiderDirector purchased ~$34K of ARQT shares in the open market
  4. May 19, 2025InsiderOfficer sold ~$105K of ARQT shares in the open market
  5. May 21, 2025InsiderDirector purchased ~$34K of ARQT shares in the open market
  6. May 22, 2025InsiderDirector purchased ~$34K of ARQT shares in the open market
  7. May 28, 2025InsiderOfficer sold ~$25K of ARQT shares in the open market
  8. Jun 4, 2025InsiderDirector purchased ~$25K of ARQT shares in the open market
  9. Jun 5, 2025InsiderDirector purchased ~$5.1K of ARQT shares in the open market
  10. Jun 13, 2025InsiderDirector purchased ~$35K of ARQT shares in the open market
  11. Jun 18, 2025InsiderDirector sold ~$136K of ARQT shares in the open market
  12. Jul 1, 2025InsiderDirector sold ~$127K of ARQT shares in the open market
  13. Jul 10, 2025InsiderOfficer sold ~$346K of ARQT shares in the open market
  14. Jul 14, 2025InsiderOfficer sold ~$87K of ARQT shares in the open market
  15. Aug 1, 2025Insider · 1 personInsiders: 2 sales (~$143K)
  16. Aug 4, 2025Insider · 4 peopleInsiders: 4 sales (~$295K)
  17. Aug 8, 2025InsiderOfficer sold ~$54K of ARQT shares in the open market
  18. Aug 19, 2025InsiderOfficer sold ~$28K of ARQT shares in the open market
  19. Aug 21, 2025InsiderOfficer sold ~$38K of ARQT shares in the open market
  20. Sep 2, 2025InsiderDirector sold ~$156K of ARQT shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Arcutis Biotherapeutics

For Arcutis Biotherapeutics, OQRO holds 13 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARQT page.

Other recent filings by Patrick J Heron, Director

The full history of Patrick J Heron, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Arcutis Biotherapeutics (ARQT) insider traded, and how much?

Patrick J Heron, Director at Arcutis Biotherapeutics, bought ~$86K of Arcutis Biotherapeutics shares. 6,300 shares at $13.60, open market.

When did it happen, and when was it made public?

Traded: May 9, 2025. Filed: May 13, 2025. That is 4 days between the two dates.

What stands out in this filing?

After this purchase the filing reports 6,300 shares, held indirectly. 6,300 shares at an average of $13.60 each, as reported on the form.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Arcutis Biotherapeutics recently?

For Arcutis Biotherapeutics, OQRO holds 13 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the ARQT page.

Does this mean ARQT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Arcutis Biotherapeutics

Everything OQRO holds on this company is on its ARQT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data